Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 1 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Recurrence 4Multiple Myeloma 4Lymphoma 4Ovarian Neoplasms 3Burkitt Lymphoma 3Neoplasms, Plasma Cell 2Nasopharyngeal Carcinoma 2Lymphoma, T-Cell 2Leukemia, Myeloid, Acute 2Solid Tumors 1Solid Tumor 1Solid Cancer 1Small Cell Lung Carcinoma 1Skin Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Polyradiculoneuropathy, Chronic Inflammatory Demyelinating 1POEMS Syndrome 1Neuromyelitis Optica 1Neuroblastoma 1Neoplasms, Neuroepithelial 1Neoplasms 1Neoplasm, Residual 1Neoplasm Metastasis 1Myositis 1Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease 1Myasthenia Gravis 1Multiple Sclerosis 1Metastatic Castration-resistant Prostate Cancer 1Melanoma 1Lymphoma, Mantle-Cell 1

Interventions

fludarabine 1alovudine 1Cyclophosphamide 1(225)Ac-PSMA-617 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Metastatic Castration-resistant Prostate Cancer × fludarabine × Clear all
NCT03692663 2022-08-01

Study of Anti-PSMA CAR NK Cell (TABP EIC) in Metastatic Castration-Resistant Prostate Cancer

Allife Medical Science and Technology Co., Ltd.

Phase EARLY_PHASE1 Unknown
9 enrolled
Genitourinary

Metastatic Castration-resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡